We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The value of molecular stratification for CEBPA<sup>DM</sup> and NPM1<sup>MUT</sup> FLT3<sup>WT</sup> genotypes in older patients with acute myeloid leukaemia.
- Authors
Dickson, Glenda J.; Bustraan, Sophia; Hills, Robert K.; Ali, Akbar; Goldstone, Anthony H.; Burnett, Alan K.; Linch, David C.; Gale, Rosemary E.
- Abstract
Older adult patients (≥60 years) with acute myeloid leukaemia ( AML) are generally considered to be poor-risk and there is limited information available regarding risk stratification based on molecular characterization in this age group, particularly for the double-mutant CEBPA ( CEBPADM) genotype. To investigate whether a molecular favourable-risk genotype can be identified, we investigated CEBPA, NPM1 and FLT3 status and prognostic impact in a cohort of 301 patients aged 60 years or more with intermediate-risk cytogenetics, all treated intensively. Overall survival ( OS) at 1 year was highest in the 12 patients (4%) that were CEBPADM compared to the 76 (28%) with a mutant NPM1 and wild-type FLT3 ( NPM1MUT FLT3WT) genotype or all other patients (75%, 54%, 33% respectively), with median survival 15·2, 13·6 and 6·6 months, although the benefit was short-term ( OS at 3 years 17%, 29%, 12% respectively). Combination of the CEBPADM and NPM1MUT FLT3WT genotype patients defined a molecular group with favourable prognosis ( P < 0·0001 in multivariate analysis), with 57% of patients alive at 1 year compared to 33% for all other patients. Knowledge of genotype in older cytogenetically intermediate-risk patients might influence therapy decisions.
- Subjects
ACUTE myeloid leukemia; GENOTYPES; CYTOGENETICS; PROGNOSIS; COHORT analysis
- Publication
British Journal of Haematology, 2016, Vol 172, Issue 4, p573
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.13873